O-2 - Adult Vaccines

Co-Author(s)

• CB

  Céline Boutry, PhD

  Dr
  Aixial, Bruxelles, Belgium, on behalf of GSK
  Bruxelles, Brussels Hoofdstedelijk Gewest, Belgium

  Disclosure: Aixial (Consultant)
• AC

  Anthony Cunningham, MBBS, MD, FRACP, FRCPA

  Professor
  The Westmead Institute for Medical Research, Westmead, NSW, Australia and University of Sydney, Sydney, NSW, Australia
  Sydney, New South Wales, Australia

  Disclosure: GSK (Consultant)
• DC

  Desmond Curran, PhD

  Director of Value Evidence
  GSK
  Wavre, Vlaams-Brabant, Belgium

  Disclosure: GSK (Employee, Shareholder)
• AD

  Alemnew Dagnew, MD

  Dr.
  GSK, Rockville, MD, United States
  Rockville, Maryland

  Disclosure: GSK group of companies (Employee, Shareholder)
• AD

  Alemnew F. Dagnew, MD, MSc

  Clinical Researcher
  GSK, Rockville, Maryland, United States
  Rockville, Maryland

  Disclosure: GSK group of companies: Employee, Shareholder
• MD

  Mitchell DeKoven, PhD

  Senior Principal
  IQVIA
  Falls Church, Virginia

  Disclosure: Seqirus Vaccines Ltd. (Consultant)
• CD

  Christophe Dessart, MSc

  Mr.
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK (Employee)
• JD

  Javier Diez-Domingo, MD

  Head of the Vaccine Research Department
  FISABIO, Valencia, Spain
  Valencia, Comunidad Valenciana, Spain

  Disclosure: GSK group of companies (Board Member, Scientific Research Study Investigator, Advisor or Review Panel member)MSD (Board Member, Scientific Research Study Investigator, Advisor or Review Panel member)
• VD

  Victoria Divino, PhD

  Associate Principal
  IQVIA
  Falls Church, Virginia

  Disclosure: Seiqrus Vaccines Ltd. (Consultant)
• MD

  Mamadou Drame, MSc

  Lead – Expert Biostatistician
  GSK, Rockville, Maryland, United States
  Rockville, Maryland

  Disclosure: GSK group of companies (Employee)
• SE

  Srikanth Emmadi, MSc

  Statistician
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK (Employee)
• WG

  William Gruber, MD

  SVP Vaccine Clinical Research and Development
  Worldwide Research, Development and Medical
  Pfizer Inc
  Pearl River, New York

  Disclosure: Pfizer (Employee, Shareholder)
• KJ

  Kathrin Jansen, PhD

  Senior Vice President, Pfizer Vaccine Research and Development
  Pfizer
  Pearl River, New York

  Disclosure: Pfizer (Employee, Shareholder)
• RJ

  Robert Johnson, MD, FRCA

  Honorary Senior Research Fellow
  Faculty of Health Sciences
  University of Bristol, Bristol, United Kingdom
  Bristol, England, United Kingdom

  Disclosure: GSK (Other Financial or Material Support, I accept no fees but have had expense reimbursement in the past.)
• GK

  George Kalema, PhD

  Dr
  Keyrus Biopharma, Waterloo, Belgium, on behalf of GSK
  Waterloo, Brabant Wallon, Belgium

  Disclosure: GSK group of companies/Keyrus Biopharma (Consultant)
• 

  Joon Hyung Kim, MD

  Dr.
  GSK
  Rockville, Maryland

  Disclosure: GSK (Employee, Shareholder)
• MK

  Martina Kovac, MD

  Dr
  GSK, Rockville, MD, United States
  Rockville, Maryland

  Disclosure: GSK (Other Financial or Material Support, I was an employee of GSK at the time of the study)
• GK

  Girishanthy Krishnarajah, PhD

  Senior Director Market Access and Strategy
  Seqirus Vaccines Ltd.
  Summit, New Jersey

  Disclosure: Seqirus Vaccines Ltd. (Employee, Shareholder)
• ml

  myron levin, MD

  Professor
  Pediatrics and Medicine
  University of Colorado Anschutz Medical Campus
  Aurora, Colorado

  Disclosure: Curevo (Advisor or Review Panel member)GlaxoSmithKline (Grant/Research Support, Advisor or Review Panel member)GlaxoSmithKline (Grant/Research Support, Advisor or Review Panel member)Merck Research Laboratories (Advisor or Review Panel member, GlaxoSmithKline)Merck Research Laboratories (Advisor or Review Panel member)Merck ResearchLaboratories (Advisor or Review Panel member)
• SM

  Sean Matthews, MSc

  Mr.
  GSK
  Dublin, Dublin, Ireland

  Disclosure: GSK (Consultant)
• SM

  Shelly McNeil, FRCPC, MD

  ID Physician
  Canadian Center for Vaccinology (CCfV), IWK Health Centre, Nova Scotia Health Authority (NSHA), and Dalhousie University, Halifax, Nova Scotia (NS)
  Halifax, Nova Scotia, Canada

  Disclosure: GSK (Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support, Other Financial or Material Support, honoraria for talks)
• LM

  Lisa Moyer, BS

  Ms
  Pfizer Inc
  Collegeville, Pennsylvania

  Disclosure: Pfizer (Employee, Shareholder)
• LO

  Lidia Oostvogels, MD

  MD
  GSK
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK (Shareholder)
• SP

  Stephen Pelton, MD

  Pediatric I D physician
  Pediatrics
  Boston Medical Center
  Boston, Massachusetts

  Disclosure: Merck vaccine (Consultant, Grant/Research Support)Pfizer (Consultant, Grant/Research Support)Sanofi Pasteur (Consultant, Other Financial or Material Support, DSMB)Seqirus Vaccine Ltd. (Consultant)
• YP

  Yahong Peng, PhD

  Sr Director, Biostatistics
  Vaccine Research and Development
  Pfizer Inc
  Collegeville, Pennsylvania

  Disclosure: Pfizer (Employee, Shareholder)
• PP

  Paola Pirrotta, PharmD

  Expert Safety Scientist
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee)
• MP

  Maarten Postma, Dr.

  Professor in Global Health Economics & Pharmacoeconomics
  University of Groningen
  Groningen, Groningen, Netherlands

  Disclosure: IQVIA (Consultant)
• MP

  Michael Pride, PhD

  Executive Director, Vaccine Research and Development
  Pfizer
  Pearl River, New York

  Disclosure: Pfizer (Employee, Shareholder)
• MR

  Megan Riley, PhD

  Clinical and Epidemiology Scientist
  GSK
  Rockville, Maryland

  Disclosure: GSK (Employee)
• CS

  Charu Sabharwal, MD, MPH

  Dr
  Pfizer Inc
  Pearl River, New York

  Disclosure: Pfizer (Employee, Shareholder)
• BS

  Bruno Salaun, PhD

  Senior Scientist
  GSK, Rixensart, Belgium
  Rixensart, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee)
• 

  Kenneth E. Schmader, MD

  Professor
  Duke University Medical Center
  Durham, North Carolina

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AS

  Anne Schuind, MD

  MD
  GSK
  Rockville, Maryland

  Disclosure: GSK (Employee, Other Financial or Material Support, own GSK stock options or restricted shares as part of renumeration)
• DS

  Daniel Scott, MD

  Vice President
  Vaccine Clinical Research and Development
  Pfizer
  Collegeville, Pennsylvania

  Disclosure: Pfizer (Employee, Shareholder)
• IS

  Ingrid Scully, PhD

  Associate Research Fellow
  Pfizer Vaccine Research and Development
  Pearl River, New York

  Disclosure: Pfizer Inc (Employee, Shareholder)
• DS

  Drishti Shah, PhD

  Consultant
  IQVIA
  Falls Church, Virginia

  Disclosure: Seqirus Vaccines Ltd. (Consultant)
• MS

  Meng Shi, MS

  Expert Statistician
  GSK, Rockville, Maryland, United States
  Rockville, Maryland

  Disclosure: GSK group of companies (Employee)
• KS

  Keith Sullivan, MD, FASTCT

  Professor of Medicine
  Duke University Medical Center, Durham, NC, United States
  Durham, North Carolina

  Disclosure: GSK (Consultant)
• VS

  Vani Sundaraiyer, PhD, MS

  Ms
  Inventiv Health Clinical LLC
  Princeton, New Jersey

  Disclosure: Pfizer (Independent Contractor)
• JT

  Juan Carlos Tinoco, MD

  MD
  Hospital General de Durango, Durango, Mexico
  Durango, Durango, Mexico

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• WW

  Wendy Watson, MD

  Senior Director
  Pfizer Vaccine Research and Development
  Collegeville, Pennsylvania

  Disclosure: Pfizer (Employee, Shareholder)
• DW

  David Willer, PhD

  Global Medical Affairs Lead - Zoster
  GSK, Mississauga, Ontario, Canada
  Mississauga, Ontario, Canada

  Disclosure: GSK group of companies (Employee, Shareholder)
• XX

  Xia Xu, PhD

  Ms
  Pfizer Inc
  Collegeville, Pennsylvania

  Disclosure: Pfizer (Employee, Shareholder)
• CY

  Chong-Jen Yu, MD

  Professor
  National Taiwan University Hospital, Taipei, Taiwan
  Taipei, Taipei

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presenting Author(s)

• 

  Melissa Andrew, MD, PhD, MSc(Ph)

  Professor
  Medicine (Geriatrics)
  Dalhousie University; Canadian Centre for Vaccinology
  Halifax, NS, Canada

  Disclosure: GSK (Grant/Research Support, Research Grant or Support)

  Slides Slides and Audio
• 

  Brandon Essink, MD CPI

  Principal Investigator
  Meridian Clinical Research Omaha, Omaha, NE, United States
  Omaha, NE

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Andrew Hastie, MD, DipPharmMed

  Senior Clinical Research & Development Lead
  GSK, Rockville, Maryland, United States
  Rockville, Maryland

  Disclosure: GSK group of companies (Employee)

  Slides Slides and Audio
• 

  Joon Hyung Kim, MD

  Dr.
  GSK
  Rockville, Maryland

  Disclosure: GSK (Employee, Shareholder)

  Slides Slides and Audio
• 

  Joaquin Mould-Quevedo, PhD

  Global Pricing and Health Economics Director
  Seqirus Vaccines Ltd.
  Summit, NJ

  Disclosure: Seqirus Vaccines Ltd. (Employee, Shareholder)

  Slides Slides and Audio
• 

  Peter Vink, MD

  Director, Senior Clinical and Scientific Expert Zoster Vaccines
  GSK, Rockville, Maryland, United States
  Rockville, MD

  Disclosure: GSK group of companies: Employee, Shareholder

  Slides Slides and Audio

Presentations:

• Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older
  Brandon Essink, MD CPI – Meridian Clinical Research Omaha, Omaha, NE, United States; Charu Sabharwal, MD, MPH – Pfizer Inc; Xia Xu, PhD – Pfizer Inc; Vani Sundaraiyer, PhD, MS – Inventiv Health Clinical LLC; Yahong Peng, PhD – Pfizer Inc; Lisa Moyer, BS – Pfizer Inc; Michael W. Pride, PhD – Pfizer; Ingrid L. Scully, PhD – Pfizer Vaccine Research and Development; Kathrin U. Jansen, PhD – Pfizer; William C. Gruber, MD – Pfizer Inc; Daniel Scott, MD – Pfizer; Wendy Watson, MD – Pfizer Vaccine Research and Development
• Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
  Alemnew F. Dagnew, MD, MSc – GSK, Rockville, Maryland, United States; Peter Vink, MD – GSK, Rockville, Maryland, United States; Mamadou Drame, MSc – GSK, Rockville, Maryland, United States; David Willer, PhD – GSK, Mississauga, Ontario, Canada; Bruno Salaun, PhD – GSK, Rixensart, Belgium; Anne Schuind, MD – GSK
• How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies
  Melissa K. Andrew, MD, PhD, MSc(Ph) – Dalhousie University; Canadian Centre for Vaccinology; Joon Hyung Kim, MD – GSK; Sean Matthews, MSc – GSK; Christophe Dessart, MSc – GSK, Wavre, Belgium; myron J. levin, MD – University of Colorado Anschutz Medical Campus; Lidia Oostvogels, MD – GSK; Megan Riley, PhD – GSK; Kenneth E. E. Schmader, MD – Duke University Medical Center; Shelly McNeil, FRCPC, MD – Canadian Center for Vaccinology (CCfV), IWK Health Centre, Nova Scotia Health Authority (NSHA), and Dalhousie University, Halifax, Nova Scotia (NS); Anne Schuind, MD – GSK; Desmond Curran, PhD – GSK
• MF59 ASSURANCE 2: A Real-world Study to Estimate the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-based Trivalent High-dose Among U.S. Older Adults During 2018-19 Influenza Season
  Stephen I. Pelton, MD – Boston Medical Center; Maarten Postma, Dr. – University of Groningen; Victoria Divino, PhD – IQVIA; Drishti Shah, PhD – IQVIA; Joaquin F. Mould-Quevedo, PhD – Seqirus Vaccines Ltd.; Mitchell DeKoven, PhD – IQVIA; Girishanthy Krishnarajah, PhD – Seqirus Vaccines Ltd.
• Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
  Joon Hyung Kim, MD – GSK; Robert Johnson, MD, FRCA – University of Bristol, Bristol, United Kingdom; Martina Kovac, MD – GSK, Rockville, MD, United States; Anthony L. Cunningham, MBBS, MD, FRACP, FRCPA – The Westmead Institute for Medical Research, Westmead, NSW, Australia and University of Sydney, Sydney, NSW, Australia; Srikanth Emmadi, MSc – GSK, Wavre, Belgium; Keith Sullivan, MD, FASTCT – Duke University Medical Center, Durham, NC, United States; Alemnew F. Dagnew, MD – GSK, Rockville, MD, United States; Desmond Curran, PhD – GSK; Anne Schuind, MD – GSK
• The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
  Céline Boutry, PhD – Aixial, Bruxelles, Belgium, on behalf of GSK; Andrew J. Hastie, MD, DipPharmMed – GSK, Rockville, Maryland, United States; Meng Shi, MS – GSK, Rockville, Maryland, United States; Javier Diez-Domingo, MD – FISABIO, Valencia, Spain; Juan Carlos Tinoco, MD – Hospital General de Durango, Durango, Mexico; Chong-Jen Yu, MD – National Taiwan University Hospital, Taipei, Taiwan; Paola Pirrotta, PharmD – GSK, Wavre, Belgium; George Kalema, PhD – Keyrus Biopharma, Waterloo, Belgium, on behalf of GSK; Anne Schuind, MD – GSK